ReviewNature reviews. Microbiology2026
The type VI secretion system and associated effector proteins.
Review in Nature reviews. Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- A type VI secretion ADP-ribosyltransferase Rhs toxin selectively modifies charged tRNAThr(GGU) anticodon loops to block ACC codon decoding.Nucleic acids research · 2026Article
- In vitro reconstitution implicates multiple OMP assembly factors in CdiAThe Journal of biological chemistry · 2026Article
- Bacterial weaponry and the ecological factors of competitive success.Essays in biochemistry · 2026Review
- It takes a village: how plant-associated bacterial communities socialise to shape plant growth and health.Essays in biochemistry · 2026Review
- GeoEPred: A multimodal structure-aware geometric deep learning framework for Gram-negative bacterial secreted effector prediction with sequence semantics.PLoS computational biology · 2026Article
- ABPs: diffusible antibacterial toxins secreted by and active against diverse gram-positive bacteria.Infection and immunity · 2026Review
- Beyond the Halo: Molecular Mechanisms and Ecological Aspects of the Infection Strategy ofInternational journal of molecular sciences · 2026Review
- An ART-fold Rhs toxin from Pluralibacter gergoviae defines Tne5, a novel family of NAD(P) glycohydrolases effectors.The Journal of biological chemistry · 2026Article
- Pan-genome insights into type VI secretion systems and their functional repertoires inmSystems · 2026Article
- "Molecular insights into the bactericidal toxin Tle1 of Pseudomonas aeruginosa: Interaction with VgrG, its adaptor, and its immunity protein".The Journal of biological chemistry · 2026Article
- Review
- Reprogrammed SimCells for antimicrobial therapy.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- T6SS mutants exploit itaconate to support infection of phagocytes.bioRxiv : the preprint server for biology · 2026Article
- The type VI secretion system of Acinetobacter: mechanisms, biology and therapeutic potential.Communications biology · 2026Review
- Type VI secretion systems at the interface between bacteria and eukaryotic cells.Genetics and molecular biology · 2026Article
- Virulence regulation in the fish pathogenFrontiers in cellular and infection microbiology · 2026Review
- The Type VI secretion system in enteric pathogen colonization: molecular mechanisms, ecological dynamics, and therapeutic potential.Frontiers in microbiology · 2026Review
- Type VI secretion system-mediated bacterial antagonism in the classroom.Access microbiology · 2026Article
- The SPI-20 and SPI-21 T6SS gene clusters fromFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria have evolved a myriad of antibacterial weapons to engage in interbacterial conflicts. Among these, many Gram-negative bacteria use type VI secretion systems (T6SSs), which are contractile toxin delivery systems, to eliminate or suppress competitors in a contact-dependent manner. Recent studies have revealed that both the toxic effector arsenals and the corresponding immunity strategies that defend against incoming T6SS attacks are far more diverse and variable than previously anticipated. This diversity is increasingly recognized as the outcome of an ongoing evolutionary arms race, driven by antagonistic interactions between bacteria. In this Review, we provide an overview of our current understanding of T6SSs, with a particular focus on the diversity of antibacterial T6SS repertoires and the evolutionary pressures shaping them. We outline the key principles underlying effector diversification and discuss the emerging role of interbacterial antagonism as a key driver of this process.
Indexed as
Identifiers
41238756What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.